New York, May 20, 2026, 17:07 EDT
- CG Oncology traded at $64.76, up 2.3%. The company is valued at roughly $5.47 billion.
- Wolfe Research started coverage with a Peer Perform, calling the view broadly neutral and pointing to questions on cretostimogene’s launch and adoption. TipRanks
- CG Oncology said its next big catalyst will be clinical. It’s looking for top-line data from its PIVOT-006 Phase 3 readout in the first half of 2026, with plans to finish its first biologics license application in the fourth quarter. CG Oncology
CG Oncology shares edged higher Wednesday as traders looked for direction and watched for the next update on its bladder-cancer drug, cretostimogene grenadenorepvec. The stock was recently quoted at $64.76, up 2.3%. Volume was near 768,000 shares.
CG Oncology isn’t just a small biotech with a long runway anymore. The stock now trades around a near-term trial readout, a planned regulatory filing, and early Wall Street arguments over how quickly the drug could move if it wins approval. The company said it plans a biologics license application, or BLA, which is the main U.S. route for getting a biologic medicine cleared. CG Oncology
CG Oncology’s main drug targets non-muscle invasive bladder cancer, or NMIBC, which has not spread into the bladder muscle. The therapy, called cretostimogene, is given directly into the bladder — an approach known as intravesical delivery. It’s classified as an oncolytic immunotherapy, designed to kill cancer cells and spark an immune response. CG Oncology said cretostimogene is still investigational and not yet approved by the FDA or any regulator. GlobeNewswire
Wolfe Research’s Kalpit Patel started coverage on CG Oncology at Peer Perform on May 19, StreetInsider reported. Wolfe pointed to PIVOT-006 and a potential approval in BCG-unresponsive NMIBC as the main catalysts, but the note said there is caution around initial commercial demand and possible use in intermediate-risk cases. BCG is a longtime immune therapy for bladder cancer; “BCG-unresponsive” refers to patients whose cancer stops responding. Streetinsider
Caution comes just days after CG Oncology put out first results from CORE-008 Cohort CX, a Phase 2 trial testing cretostimogene with gemcitabine. According to the company, high-grade event-free survival stood at 96.0% at three months and 89.5% at six months. Complete response rates in carcinoma in situ patients were 85.7% and 92.3% in two groups. GlobeNewswire
CG Oncology Chief Medical Officer Vijay Kasturi called the early data “robust clinical activity” with a “favorable safety profile.” Trinity Bivalacqua, a University of Pennsylvania urologist running the cohort, said the study showed responses were consistent in both BCG-exposed and BCG-unresponsive patients. CG Oncology
CG Oncology has finished the clinical and non-clinical modules for its first BLA, the company told investors. CEO Arthur Kuan said the last piece, the manufacturing module, is progressing and that CG Oncology is “on track to finalize” the full submission in the fourth quarter of 2026. CG Oncology
J&J’s Inlexzo, previously called TAR-200, got U.S. FDA approval in September 2025 for adults with BCG-unresponsive NMIBC with carcinoma in situ, with or without papillary tumors. The FDA reported an 82% complete response rate for Inlexzo. Of the patients who responded, 51% saw their response last at least a year. U.S. Food and Drug Administration
But there’s not much room for error here. Cretostimogene hasn’t been approved, interim trial results could move as follow-up continues, and Wolfe’s warning flags a tougher road if Johnson & Johnson’s Inlexzo gets more traction in urology clinics before CG Oncology’s drug arrives. Any slip, like a delayed BLA, rough PIVOT-006 numbers, or slow rollout, could put pressure on shares that have run up. TipRanks
Tech bulls steered Wednesday’s session. Wall Street’s big indexes finished up more than 1%, paced by gains in tech and chip names ahead of Nvidia’s report. “Technology is driving the bus,” BMO Private Wealth strategist Carol Schleif told Reuters, adding that growth and biotech shares got a firmer bid compared to earlier in the week. Reuters
CG Oncology’s most recent announcement as of May 19 wasn’t about a new trial or regulatory development. This time, the company named Patrick Hensley from the University of Kentucky Research Foundation and Daniel Joyce at Vanderbilt University Medical Center as winners of NMIBC research fellowship grants, each able to receive up to $50,000. BioSpace
Stock watchers still don’t have a clear signal on the next move. The timeline is public. Combination data is out. Wolfe has started coverage, neutral. But there’s no PIVOT-006 result yet, so investors can’t tell if Wednesday’s action was just a bounce or something bigger.
